{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:08:55Z","timestamp":1791428935485,"version":"4.3.3"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,5,26]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICPi) are a novel and promising anti-cancer therapy. There are limited data on the incidence, risk factors and outcomes of acute kidney injury (AKI) in patients receiving ICPi.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a cohort study of patients receiving ICPi at our center between 2010 and 2017 via electronic health record. The primary outcome was AKI (increase of &gt;50% from baseline serum creatinine (sCr)). Risk factors for AKI were assessed using logistic regression. Survival among those with and without AKI was compared using the Kaplan-Meier method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 309 patients on ICPi, 51 (16.5%) developed AKI (Kidney Disease Improving Global Outcomes (KDIGO) stages 1: 53%, 2: 22%, 3: 25%). AKI was associated with other immune-related adverse events (IRAE) (OR 3.2, 95% CI 1.6 to 6; p&lt;0.001), hypertension (OR 4.3, 95% CI 1.8 to 6.1; p&lt;0.001) and cerebrovascular disease (OR 9.2; 95% CI 2.1 to 40; p&lt;0.001). Baseline sCr, cancer, and ICPi type was not associated with AKI. Use of angiotensin-converting enzyme inhibitors\/angiotensin-receptor blockers (OR 2.9; 95% CI 1.5 to 5.7; p=0.002), diuretics (OR 4.3; 95% CI 1.9 to 9.8; p&lt;0.001), and corticosteroid treatment (OR 1.9; 95% CI 1.1 to 3.6; p=0.03) were associated with AKI. In the multivariable analysis, AKI was associated only with other IRAE (OR 2.82; 95% CI 1.45 to 5.48; p=0.002) and hypertension (OR 2.96; 95% CI 1.33 to 6.59; p=0.008). AKI was not associated with increased risk of mortality (HR 1.1; 95% CI: 0.8 to 1.6; p=0.67). ICPi nephrotoxicity was attributed via biopsy or nephrologist assessment in 12 patients (six interstitial nephritis, two membranous nephropathy, two minimal change disease, and two thrombotic microangiopathy). Subsequent doses of ICPi were administered to 12 patients with prior AKI, with one (8.3%) having recurrent AKI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>AKI is a common complication in patients receiving ICPi treatment. The development of other IRAE and previous diagnosis of hypertension were associated with increased AKI risk. AKI was not associated with worse survival. Distinguishing kidney IRAE from other causes of AKI will present a frequent challenge to oncology and nephrology practitioners. Kidney biopsy should be considered to characterize kidney lesions and guide potential therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2019-000467","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T02:19:49Z","timestamp":1593483589000},"page":"e000467","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":172,"title":["Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8174-1235","authenticated-orcid":false,"given":"Alejandro","family":"Meraz-Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology and Hematology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Avila-Casado","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ragobar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Wald","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Unity Health, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-5046","authenticated-orcid":false,"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"2025100308053210000_8.1.e000467.1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","article-title":"Cardiorenal complications of immune checkpoint inhibitors","volume":"14","author":"Sury","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2025100308053210000_8.1.e000467.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025100308053210000_8.1.e000467.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.03.433"},{"key":"2025100308053210000_8.1.e000467.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008"},{"key":"2025100308053210000_8.1.e000467.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.02.057"},{"key":"2025100308053210000_8.1.e000467.6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2025100308053210000_8.1.e000467.7","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy100"},{"key":"2025100308053210000_8.1.e000467.8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0478-8"},{"key":"2025100308053210000_8.1.e000467.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389"},{"key":"2025100308053210000_8.1.e000467.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160221"},{"key":"2025100308053210000_8.1.e000467.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"2025100308053210000_8.1.e000467.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1167"},{"key":"2025100308053210000_8.1.e000467.13","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2025100308053210000_8.1.e000467.14","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000852019"},{"key":"2025100308053210000_8.1.e000467.15","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025100308053210000_8.1.e000467.16","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03140312"},{"key":"2025100308053210000_8.1.e000467.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1613984"},{"key":"2025100308053210000_8.1.e000467.18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.6627","article-title":"Modeling the cost of immune checkpoint inhibitor-related toxicities","volume":"34","author":"Mason","year":"2016","journal-title":"JCO"},{"key":"2025100308053210000_8.1.e000467.19","first-page":"761","article-title":"Incidence of AKI in immune checkpoint inhibitors, single center study [Abstract]","volume":"26","author":"Hirsch","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2025100308053210000_8.1.e000467.20","doi-asserted-by":"publisher","DOI":"10.1159\/000455014"},{"key":"2025100308053210000_8.1.e000467.21","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00990119"},{"key":"2025100308053210000_8.1.e000467.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2011.05.005"},{"key":"2025100308053210000_8.1.e000467.23","first-page":"727","article-title":"Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study","volume":"11","author":"Kitchlu","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2025100308053210000_8.1.e000467.24","doi-asserted-by":"crossref","unstructured":"Kim Y . Relapse of membranous nephropathy with cancer immunotherapy. Clin Kidney J 2019:1\u20133.","DOI":"10.1093\/ckj\/sfz074"},{"key":"2025100308053210000_8.1.e000467.25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e15083","article-title":"Checkpoint inhibitor induced glomerulonephritis","volume":"36","author":"Abudayyeh","year":"2018","journal-title":"JCO"},{"key":"2025100308053210000_8.1.e000467.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0904283"},{"key":"2025100308053210000_8.1.e000467.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100308053210000_8.1.e000467.28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/ckj\/sfy114","article-title":"Pembrolizumab-related renal toxicities: diagnosis first, treatment later","volume":"12","author":"Sprangers","year":"2019","journal-title":"Clin Kidney J"},{"key":"2025100308053210000_8.1.e000467.29","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019070676"},{"key":"2025100308053210000_8.1.e000467.30","doi-asserted-by":"publisher","DOI":"10.1186\/cc5713"},{"key":"2025100308053210000_8.1.e000467.31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"2025100308053210000_8.1.e000467.32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7260"},{"key":"2025100308053210000_8.1.e000467.33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2019-000467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:05:55Z","timestamp":1759503955000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,6,29]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/jitc-2019-000467"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2019-000467","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}